Q
39.10
1.05 (2.76%)
| Penutupan Terdahulu | 38.05 |
| Buka | 38.51 |
| Jumlah Dagangan | 418,992 |
| Purata Dagangan (3B) | 687,271 |
| Modal Pasaran | 2,628,903,936 |
| Harga / Pendapatan (P/E Ke hadapan) | 16.29 |
| Harga / Jualan (P/S) | 0.980 |
| Harga / Buku (P/B) | 0.870 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Nov 2024 |
| Margin Keuntungan | -66.25% |
| Margin Operasi (TTM) | 7.12% |
| EPS Cair (TTM) | -27.81 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -2.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 87.23% |
| Nisbah Semasa (MRQ) | 1.38 |
| Aliran Tunai Operasi (OCF TTM) | 99.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 158.72 M |
| Pulangan Atas Aset (ROA TTM) | 1.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | QuidelOrtho Corporation | Menurun | Menurun |
AISkor Stockmoo
0.2
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 5.0 |
| Purata | 0.20 |
|
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.46% |
| % Dimiliki oleh Institusi | 96.21% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 57.00 (Craig-Hallum, 45.78%) | Beli |
| Median | 53.50 (36.83%) | |
| Rendah | 50.00 (UBS, 27.88%) | Pegang |
| Purata | 53.50 (36.83%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 45.37 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 19 Sep 2024 | 50.00 (27.88%) | Pegang | 46.23 |
| Craig-Hallum | 05 Sep 2024 | 57.00 (45.78%) | Beli | 44.50 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CARLYLE GROUP INC. | - | 37.89 | -8,260,183 | -312,978,334 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,260,183 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -312,978,334 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 37.89 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CARLYLE GROUP INC. | 21 Nov 2024 | Jual (-) | 8,260,183 | 37.89 | 312,978,334 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Nov 2024 | Pengumuman | QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group |
| 19 Nov 2024 | Pengumuman | QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group |
| 07 Nov 2024 | Pengumuman | QuidelOrtho Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | Pengumuman | QuidelOrtho to Participate in Three Upcoming Investor Conferences |
| 17 Oct 2024 | Pengumuman | QuidelOrtho to Report Third Quarter 2024 Financial Results |
| 09 Oct 2024 | Pengumuman | QuidelOrtho Announces New R&D Executive Leader |
| 10 Sep 2024 | Pengumuman | QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |